Drugs / sumanirole
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00058838 | Apr 2003 → Sep 2004 | Parkinson disease | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00036218 | Dec 2001 → Apr 2003 | Parkinson disease | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00036205 | Aug 2000 → Dec 2004 | Parkinson disease | Pfizer | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sumanirole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00058838 ↗ |
| Known as | Pnu-95666 | ChEMBL registry synonym — accepted as the source's own label CHEMBL419792 ↗ |
| Known as | PNU-95666E | ChEMBL registry synonym — accepted as the source's own label CHEMBL419792 ↗ |
| Known as | Sumanirol | ChEMBL registry synonym — accepted as the source's own label CHEMBL419792 ↗ |
| Action | Activate | “Dopamine D2 receptor agonist” CHEMBL419792 ↗ |
| Modality | Small molecule | — CHEMBL419792 ↗ |
| Target | DRD2 | “Dopamine D2 receptor agonist” CHEMBL419792 ↗ |